Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov;102(6):1069-1077.
doi: 10.1002/ccd.30891. Epub 2023 Oct 23.

The evolution and revolution of drug coated balloons in coronary angioplasty: An up-to-date review of literature data

Bernardo Cortese  1   2   3 , Harkaran Kalkat  4 , Gurbir Bathia  5 , Sandeep Basavarajaiah  5
Affiliations
Review

The evolution and revolution of drug coated balloons in coronary angioplasty: An up-to-date review of literature data

Bernardo Cortese et al. Catheter Cardiovasc Interv. 2023 Nov.

Abstract

European Society of Cardiology (ESC) guidelines gave class I A indication for use of DCB in in-stent restenosis. However, no indication exists for the usage of DCB in de novo lesions. Although the current generation DES offer excellent results, as we embark more complex lesions such as calcified lesion and chronic total occlusion, restenosis and stent thrombosis are higher and tend to increase within the years. There is increasing desire to leave nothing behind to abolish the risk of restenosis and stent thrombosis and hence the absorbable scaffolds were introduced, but with disappointing results. In addition, they take several years to be absorbed. Drug coated balloons offer an alternative to stents with no permanent implant of metal or polymer. They are already in use in in Europe and Asia and they have been approved for the first time in the United States for clinical trials specifically for restenotic lesions. There is emerging data in de novo lesions which have shown that DCB are noninferior and in some studies maybe even superior to current generation DES especially in small vessels. In this article, we provide a comprehensive review of the literature on this expanding technology focussing on the evidence in both re-stenotic and de novo lesions.

Keywords: DCB; drug-coated balloons.

PubMed Disclaimer

References

REFERENCES

    1. Haude M, Erbel R, Issa H, Meyer J. Quantitative analysis of elastic recoil after balloon angioplasty and after intracoronary implantation of balloon-expandable Palmaz-Schatz stents. JACC. 1993;21(1):26-34. doi:10.1016/0735-1097(93)90713-B
    1. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331(8):489-495. doi:10.1056/NEJM199408253310801
    1. Meraj PM, Jauhar R, Singh A. Bare metal stents versus drug eluting stents: where do we stand in 2015? Curr Treat Options Cardiovasc Med. 2015;17(8):39. doi:10.1007/S11936-015-0393-Y/METRICS
    1. Wernick MH, Jeremias A, Carrozza JP. Drug-eluting stents and stent thrombosis: a cause for concern? Coron Artery Dis. 2006;17(8):661-665. doi:10.1097/MCA.0B013E32801122B1
    1. Buccheri D, Piraino D, Andolina G, Cortese B. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. J Thorac Dis. 2016;8(10):E1150-E1162. doi:10.21037/JTD.2016.10.93

MeSH terms

Substances

LinkOut - more resources